<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01393821</url>
  </required_header>
  <id_info>
    <org_study_id>MC10C9</org_study_id>
    <secondary_id>NCI-2011-01047</secondary_id>
    <nct_id>NCT01393821</nct_id>
  </id_info>
  <brief_title>Menadione Topical Lotion in Treating Skin Discomfort and Psychological Distress in Patients With Cancer Receiving Panitumumab, Erlotinib Hydrochloride, or Cetuximab</brief_title>
  <official_title>A Randomized, Double-Blind Placebo-Controlled Exploration of a Topical Menadione-Containing Lotion to the Face for Prevention and Palliation of Epidermal Growth Factor Receptor Inhibitor-Induced Cutaneous Discomfort and Psychological Distress</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical trial studies menadione topical lotion in treating skin discomfort and
      psychological distress in patients with cancer receiving panitumumab, erlotinib
      hydrochloride, or cetuximab. Menadione topical lotion may prevent rash or other skin
      discomfort and help alleviate psychological distress and pain in patients receiving treatment
      with panitumumab, erlotinib hydrochloride, or cetuximab
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. Explore the effectiveness of a menadione topical lotion to the face to prevent cutaneous
      and psychological discomfort from epidermal growth factor receptor (EGFR) inhibitors.

      SECONDARY OBJECTIVES:

      I. Explore the adverse event profile of a menadione topical lotion to the face to prevent
      rash from EGFR inhibitors.

      II. Explore whether rash or adverse events worsen over a 4 week period after this 4-week
      intervention.

      OUTLINE: Patients are randomized to 1 of 2 treatment arms.

      ARM I: Patients apply menadione topical lotion twice daily (BID) for 28 days.

      ARM II: Patients apply topical placebo lotion BID for 28 days.

      After completion of study treatment, patients are followed up for 4 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 2012</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Actual">May 11, 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline to Week 4 Face Pain Score Measuring Cutaneous Discomfort</measure>
    <time_frame>From Baseline to Week 4</time_frame>
    <description>Change from baseline to Week 4 Face pain score measuring cutaneous discomfort. Face pain scale question (&quot;How would you describe how your face feels?&quot;) with a 0-10 Face Pain Scale, where 0 = No pain/burning and 10 = worst possible pain/burning.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Number of Patients Experiencing Worst Toxicity</measure>
    <time_frame>Up to 8 weeks</time_frame>
    <description>The number of patients experiencing treatment-related adverse events (toxicities) is reported below. The maximum grade toxicity (worst toxicity) is reported by arm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Long-term Cutaneous Discomfort as Measured by the Change From Baseline in Face Pain Scale at 4 Weeks (Treatment-regimen Estimand)</measure>
    <time_frame>Baseline, 4 weeks</time_frame>
    <description>Least Squares mean (LS) of the Face Pain Scale change from baseline at week 4 was adjusted by treatment, week, race, gender, age (&lt;=50 years/&gt;50 years), and EGFR, via a MMRM analysis. Face pain scale question (&quot;How would you describe how your face feels?&quot;) with a 0-10 Face Pain Scale, where 0 = No pain/burning and 10 = worst possible pain/burning.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Long-term Psychosocial Discomfort as Measured by the Change From Baseline in Psychological Distress Score at 4 Weeks (Treatment-regimen Estimand)</measure>
    <time_frame>Baseline, Week 4</time_frame>
    <description>Least Squares mean (LS) of the Psychological Distress Score change from baseline at week 4 was adjusted by treatment, week, race, gender, age (&lt;=50 years/&gt;50 years), and EGFR, via a MMRM analysis. Psychological Distress question (&quot;How often have you been bothered by embarrassment about your face?&quot;) with a 0-6 scale, where 0 = Never bothered and 6 = Always bothered.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Dermatologic Complications</condition>
  <condition>Malignant Neoplasm</condition>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Arm I (lotion)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients apply menadione topical lotion BID for 28 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (placebo)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients apply topical placebo lotion BID for 28 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>menadione topical lotion</intervention_name>
    <description>Given topically</description>
    <arm_group_label>Arm I (lotion)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Given topically</description>
    <arm_group_label>Arm II (placebo)</arm_group_label>
    <other_name>PLCB</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>questionnaire administration</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Arm I (lotion)</arm_group_label>
    <arm_group_label>Arm II (placebo)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>management of therapy complications</intervention_name>
    <description>Given menadione topical lotion</description>
    <arm_group_label>Arm I (lotion)</arm_group_label>
    <other_name>complications of therapy, management of</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 years or older.

          -  Patient scheduled to start an epidermal growth factor receptor inhibitor (must be one
             of these three: panitumumab, erlotinib, cetuximab) within the next 3 days or patient
             has already started the epidermal growth factor receptor inhibitor but has not been on
             it for longer than 3 days and has no signs or symptoms potentially suggestive of EGFR
             inhibitor toxicity.

          -  Ability to reliably apply Menadione Topical Lotion / placebo twice a day to the face.

          -  Ability to complete questionnaire(s) by themselves or with assistance.

          -  Negative pregnancy test (serum or urine) done â‰¤ 7 days prior to registration, for
             women of childbearing potential only.

          -  Willing to have photographs taken to assess rash.

        Exclusion Criteria:

          -  Any active facial and/or chest rash, including adult acne, at the time of
             randomization.

          -  Cutaneous metastases, skin cancer, or a history of precancerous skin lesions involving
             the face and/or chest.

          -  Use of topical corticosteroids on the face and/or chest at the time of study entry or
             their anticipated use in the next 8 weeks.

          -  Any type of ongoing therapy for rash.

          -  Any of the following:

               -  Pregnant women

               -  Nursing women

               -  Men or women of childbearing potential who are unwilling to employ adequate
                  contraception since this study involves agents that have known genotoxic,
                  mutagenic and teratogenic effects

          -  Use of any antibiotic at the time of study or their anticipated use in the 8 weeks
             immediately following study enrollment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aminah Jatoi, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic Campus in Arizona</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85054</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>June 27, 2011</study_first_submitted>
  <study_first_submitted_qc>July 12, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 13, 2011</study_first_posted>
  <results_first_submitted>September 24, 2019</results_first_submitted>
  <results_first_submitted_qc>September 24, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">October 16, 2019</results_first_posted>
  <last_update_submitted>February 18, 2020</last_update_submitted>
  <last_update_submitted_qc>February 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Arm A (Menadione)</title>
          <description>Patients apply menadione topical lotion BID for 28 days.</description>
        </group>
        <group group_id="P2">
          <title>Arm B (Placebo)</title>
          <description>Patients apply topical placebo lotion BID for 28 days.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Cancel</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>not evaluable for primary endpoint</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Excludes cancel patients who never received treatment.</population>
      <group_list>
        <group group_id="B1">
          <title>Arm A (Menadione)</title>
          <description>Patients apply menadione topical lotion BID for 28 days.</description>
        </group>
        <group group_id="B2">
          <title>Arm B (Placebo)</title>
          <description>Patients apply topical placebo lotion BID for 28 days.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="13"/>
            <count group_id="B2" value="12"/>
            <count group_id="B3" value="25"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62.5" spread="9.3"/>
                    <measurement group_id="B2" value="64.3" spread="12.6"/>
                    <measurement group_id="B3" value="63.4" spread="10.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline to Week 4 Face Pain Score Measuring Cutaneous Discomfort</title>
        <description>Change from baseline to Week 4 Face pain score measuring cutaneous discomfort. Face pain scale question (&quot;How would you describe how your face feels?&quot;) with a 0-10 Face Pain Scale, where 0 = No pain/burning and 10 = worst possible pain/burning.</description>
        <time_frame>From Baseline to Week 4</time_frame>
        <population>Patients who completed the face pain question at baseline and week 4 are included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A (Menadione)</title>
            <description>Patients apply menadione topical lotion BID for 28 days.</description>
          </group>
          <group group_id="O2">
            <title>Arm B (Placebo)</title>
            <description>Patients apply topical placebo lotion BID for 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 4 Face Pain Score Measuring Cutaneous Discomfort</title>
          <description>Change from baseline to Week 4 Face pain score measuring cutaneous discomfort. Face pain scale question (&quot;How would you describe how your face feels?&quot;) with a 0-10 Face Pain Scale, where 0 = No pain/burning and 10 = worst possible pain/burning.</description>
          <population>Patients who completed the face pain question at baseline and week 4 are included in this analysis.</population>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="0.0" upper_limit="4.0"/>
                    <measurement group_id="O2" value="3.0" lower_limit="0.0" upper_limit="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.6311</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Number of Patients Experiencing Worst Toxicity</title>
        <description>The number of patients experiencing treatment-related adverse events (toxicities) is reported below. The maximum grade toxicity (worst toxicity) is reported by arm.</description>
        <time_frame>Up to 8 weeks</time_frame>
        <population>Excludes cancel patients who never received treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A (Menadione)</title>
            <description>Patients apply menadione topical lotion BID for 28 days.</description>
          </group>
          <group group_id="O2">
            <title>Arm B (Placebo)</title>
            <description>Patients apply topical placebo lotion BID for 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Patients Experiencing Worst Toxicity</title>
          <description>The number of patients experiencing treatment-related adverse events (toxicities) is reported below. The maximum grade toxicity (worst toxicity) is reported by arm.</description>
          <population>Excludes cancel patients who never received treatment.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Grade 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Long-term Cutaneous Discomfort as Measured by the Change From Baseline in Face Pain Scale at 4 Weeks (Treatment-regimen Estimand)</title>
        <description>Least Squares mean (LS) of the Face Pain Scale change from baseline at week 4 was adjusted by treatment, week, race, gender, age (&lt;=50 years/&gt;50 years), and EGFR, via a MMRM analysis. Face pain scale question (&quot;How would you describe how your face feels?&quot;) with a 0-10 Face Pain Scale, where 0 = No pain/burning and 10 = worst possible pain/burning.</description>
        <time_frame>Baseline, 4 weeks</time_frame>
        <population>Excludes cancel patients who never received treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A (Menadione)</title>
            <description>Patients apply menadione topical lotion BID for 28 days.</description>
          </group>
          <group group_id="O2">
            <title>Arm B (Placebo)</title>
            <description>Patients apply topical placebo lotion BID for 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Long-term Cutaneous Discomfort as Measured by the Change From Baseline in Face Pain Scale at 4 Weeks (Treatment-regimen Estimand)</title>
          <description>Least Squares mean (LS) of the Face Pain Scale change from baseline at week 4 was adjusted by treatment, week, race, gender, age (&lt;=50 years/&gt;50 years), and EGFR, via a MMRM analysis. Face pain scale question (&quot;How would you describe how your face feels?&quot;) with a 0-10 Face Pain Scale, where 0 = No pain/burning and 10 = worst possible pain/burning.</description>
          <population>Excludes cancel patients who never received treatment.</population>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1820" spread="0.5003"/>
                    <measurement group_id="O2" value="1.8244" spread="0.4376"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Long-term Psychosocial Discomfort as Measured by the Change From Baseline in Psychological Distress Score at 4 Weeks (Treatment-regimen Estimand)</title>
        <description>Least Squares mean (LS) of the Psychological Distress Score change from baseline at week 4 was adjusted by treatment, week, race, gender, age (&lt;=50 years/&gt;50 years), and EGFR, via a MMRM analysis. Psychological Distress question (&quot;How often have you been bothered by embarrassment about your face?&quot;) with a 0-6 scale, where 0 = Never bothered and 6 = Always bothered.</description>
        <time_frame>Baseline, Week 4</time_frame>
        <population>Excludes cancel patients who never received treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A (Menadione)</title>
            <description>Patients apply menadione topical lotion BID for 28 days.</description>
          </group>
          <group group_id="O2">
            <title>Arm B (Placebo)</title>
            <description>Patients apply topical placebo lotion BID for 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Long-term Psychosocial Discomfort as Measured by the Change From Baseline in Psychological Distress Score at 4 Weeks (Treatment-regimen Estimand)</title>
          <description>Least Squares mean (LS) of the Psychological Distress Score change from baseline at week 4 was adjusted by treatment, week, race, gender, age (&lt;=50 years/&gt;50 years), and EGFR, via a MMRM analysis. Psychological Distress question (&quot;How often have you been bothered by embarrassment about your face?&quot;) with a 0-6 scale, where 0 = Never bothered and 6 = Always bothered.</description>
          <population>Excludes cancel patients who never received treatment.</population>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7196" spread="0.3436"/>
                    <measurement group_id="O2" value="1.1891" spread="0.3043"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 8 weeks</time_frame>
      <desc>Excludes cancel patients who never received treatment.</desc>
      <group_list>
        <group group_id="E1">
          <title>Arm A (Menadione)</title>
          <description>Patients apply menadione topical lotion BID for 28 days.</description>
        </group>
        <group group_id="E2">
          <title>Arm B (Placebo)</title>
          <description>Patients apply topical placebo lotion BID for 28 days.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 12</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Stroke</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain of skin</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 12</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Mucositis oral</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Facial pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Erythema multiforme</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Pain of skin</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="12"/>
                <counts group_id="E2" events="11" subjects_affected="9" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" events="16" subjects_affected="10" subjects_at_risk="12"/>
                <counts group_id="E2" events="16" subjects_affected="12" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Skin and subcutaneous tissue disorders - Other, specify</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Aminah Jatoi, M.D.</name_or_title>
      <organization>Mayo Clinic</organization>
      <phone>(507) 284-7202</phone>
      <email>Jatoi.Aminah@mayo.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

